MDx Impact Grants 2025-2026
Ends on
The MDx Impact Grants aim to unlock the potential of PCR to democratise access to accurate diagnostic tests that improve patient outcomes.
We invite research groups to work with us and our partner Seegene to develop tests that address unmet clinical needs. The programme provides researchers with access to Seegene’s syndromic PCR technology and development grants of up to 600,000 USD to perform clinical studies.
Each research group is permitted to submit only one application focused on the designated project. We welcome applications from eligible research groups from around the world.
2025 Scope: Urinary Tract Infection (UTI) Drug Resistance (DR)
This year, the MDx Impact Grants focus on Urinary Tract Infection (UTI) Drug Resistance (DR) genes that correspond to clinically important antibiotic resistance genes, such as, CTX-M, KPC, NDM and vanA. Your proposal must include a minimum of nine (9) and up to a maximum of eighteen (18) target genes excluding internal controls.
About your application
As Submittable is the primary communication channel used in the management of Nature Awards grants processes, please ensure that your email security settings are configured to allow receipt of emails sent from the Submittable server and/or Submittable is 'whitelisted'.
You are advised to prepare your application in a standalone document first before copying the elements into this form and to retain this document and share it with your institution's signing officer.
Please note that you are also expected to warrant that you have shared the MDx Impact Grant’s pro forma service agreement with your institution's funding office and received in principle approval, that requires no more than minor changes.
Links
To view the website homepage, please visit: www.nature.com/immersive/mdximpactgrants
The full Terms and Conditions of entry: www.nature.com/immersive/mdximpactgrants/terms-and-conditions/index.html
Further enquiries: mdximpactgrants@springernature.com